JSP191 (Briquilimab)

A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects With Lower-Risk Myelodysplastic Syndrome (LR-MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
Jasper Therapeutics, Inc.
Tags
Monoclonal Antibody
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1751
NCT Identifier
NCT05903274

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.